Immunotherapy using anti-PD-1 blockade has demonstrated significant clinical activity across a range of malignancies and anti-PD-1/CTLA-4 dual blockade has shown superiority compared to the corresponding monotherapies in melanoma, MSI-high colorectal and renal cell cancer [9]. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.